157 related articles for article (PubMed ID: 30167736)
1. Innate immune activity as a predictor of persistent insulin secretion and association with responsiveness to CTLA4-Ig treatment in recent-onset type 1 diabetes.
Cabrera SM; Engle S; Kaldunski M; Jia S; Geoffrey R; Simpson P; Szabo A; Speake C; Greenbaum CJ; ; Chen YG; Hessner MJ
Diabetologia; 2018 Nov; 61(11):2356-2370. PubMed ID: 30167736
[TBL] [Abstract][Full Text] [Related]
2. Innate immune stimulation of whole blood reveals IFN-1 hyper-responsiveness in type 1 diabetes.
Rodrigues KB; Dufort MJ; Llibre A; Speake C; Rahman MJ; Bondet V; Quiel J; Linsley PS; Greenbaum CJ; Duffy D; Tarbell KV
Diabetologia; 2020 Aug; 63(8):1576-1587. PubMed ID: 32500289
[TBL] [Abstract][Full Text] [Related]
3. CTLA4-Ig (abatacept): a promising investigational drug for use in type 1 diabetes.
Rachid O; Osman A; Abdi R; Haik Y
Expert Opin Investig Drugs; 2020 Mar; 29(3):221-236. PubMed ID: 32031422
[No Abstract] [Full Text] [Related]
4. Investigation of coordination and order in transcription regulation of innate and adaptive immunity genes in type 1 diabetes.
Gao S; Wolanyk N; Chen Y; Jia S; Hessner MJ; Wang X
BMC Med Genomics; 2017 Jan; 10(1):7. PubMed ID: 28143555
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-1 antagonism moderates the inflammatory state associated with Type 1 diabetes during clinical trials conducted at disease onset.
Cabrera SM; Wang X; Chen YG; Jia S; Kaldunski ML; Greenbaum CJ; ; Mandrup-Poulsen T; ; Hessner MJ
Eur J Immunol; 2016 Apr; 46(4):1030-46. PubMed ID: 26692253
[TBL] [Abstract][Full Text] [Related]
6. B lymphocyte alterations accompany abatacept resistance in new-onset type 1 diabetes.
Linsley PS; Greenbaum CJ; Speake C; Long SA; Dufort MJ
JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30830871
[TBL] [Abstract][Full Text] [Related]
7. Effects of CD28 blockade on subsets of naïve T cells in cats.
Aronson LR; Drobatz KJ; Hunter CA; Mason N
Am J Vet Res; 2005 Mar; 66(3):483-92. PubMed ID: 15822594
[TBL] [Abstract][Full Text] [Related]
8. Effects of CTLA4-Ig treatment on circulating fibrocytes and skin fibroblasts from the same systemic sclerosis patients: an in vitro assay.
Cutolo M; Soldano S; Montagna P; Trombetta AC; Contini P; Ruaro B; Sulli A; Scabini S; Stratta E; Paolino S; Pizzorni C; Smith V; Brizzolara R
Arthritis Res Ther; 2018 Jul; 20(1):157. PubMed ID: 30053831
[TBL] [Abstract][Full Text] [Related]
9. An improved clinical model to predict stimulated C-peptide in children with recent-onset type 1 diabetes.
Buchanan K; Mehdi AM; Hughes I; Cotterill A; Le Cao KA; Thomas R; Harris M
Pediatr Diabetes; 2019 Mar; 20(2):166-171. PubMed ID: 30556344
[TBL] [Abstract][Full Text] [Related]
10. CTLA4-Ig Effectively Controls Clinical Deterioration and Immune Condition in a Murine Model of Foxp3 Deficiency.
Gerbaux M; Roos E; Willemsen M; Staels F; Neumann J; Bücken L; Haughton J; Yshii L; Dooley J; Schlenner S; Humblet-Baron S; Liston A
J Clin Immunol; 2023 Aug; 43(6):1393-1402. PubMed ID: 37156988
[TBL] [Abstract][Full Text] [Related]
11. TLR2 and TLR4 expression on CD14(++) and CD14(+) monocyte subtypes in adult-onset autoimmune diabetes.
Cejkova P; Nemeckova I; Broz J; Cerna M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2016 Mar; 160(1):76-83. PubMed ID: 25942429
[TBL] [Abstract][Full Text] [Related]
12. Cell type-specific immune phenotypes predict loss of insulin secretion in new-onset type 1 diabetes.
Dufort MJ; Greenbaum CJ; Speake C; Linsley PS
JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30830868
[TBL] [Abstract][Full Text] [Related]
13. Treg gene signatures predict and measure type 1 diabetes trajectory.
Pesenacker AM; Chen V; Gillies J; Speake C; Marwaha AK; Sun A; Chow S; Tan R; Elliott T; Dutz JP; Tebbutt SJ; Levings MK
JCI Insight; 2019 Mar; 4(6):. PubMed ID: 30730852
[TBL] [Abstract][Full Text] [Related]
14. GAD treatment and insulin secretion in recent-onset type 1 diabetes.
Ludvigsson J; Faresjö M; Hjorth M; Axelsson S; Chéramy M; Pihl M; Vaarala O; Forsander G; Ivarsson S; Johansson C; Lindh A; Nilsson NO; Aman J; Ortqvist E; Zerhouni P; Casas R
N Engl J Med; 2008 Oct; 359(18):1909-20. PubMed ID: 18843118
[TBL] [Abstract][Full Text] [Related]
15. Effect of cholecalciferol as adjunctive therapy with insulin on protective immunologic profile and decline of residual β-cell function in new-onset type 1 diabetes mellitus.
Gabbay MA; Sato MN; Finazzo C; Duarte AJ; Dib SA
Arch Pediatr Adolesc Med; 2012 Jul; 166(7):601-7. PubMed ID: 22751874
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic T lymphocyte antigen 4 gene polymorphism confers susceptibility to type 1 diabetes in Japanese children: analysis of association with HLA genotypes and autoantibodies.
Kikuoka N; Sugihara S; Yanagawa T; Ikezaki A; Kim HS; Matsuoka H; Kobayashi Y; Wataki K; Konda S; Sato H; Miyamoto S; Sasaki N; Sakamaki T; Niimi H; Murata M
Clin Endocrinol (Oxf); 2001 Nov; 55(5):597-603. PubMed ID: 11894970
[TBL] [Abstract][Full Text] [Related]
17. Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis.
Perdigoto AL; Preston-Hurlburt P; Clark P; Long SA; Linsley PS; Harris KM; Gitelman SE; Greenbaum CJ; Gottlieb PA; Hagopian W; Woodwyk A; Dziura J; Herold KC;
Diabetologia; 2019 Apr; 62(4):655-664. PubMed ID: 30569273
[TBL] [Abstract][Full Text] [Related]
18. Plasma-induced signatures reveal an extracellular milieu possessing an immunoregulatory bias in treatment-naive paediatric inflammatory bowel disease.
Gurram B; Salzman NH; Kaldunski ML; Jia S; Li BU; Stephens M; Sood MR; Hessner MJ
Clin Exp Immunol; 2016 Apr; 184(1):36-49. PubMed ID: 26660358
[TBL] [Abstract][Full Text] [Related]
19. Molecular signatures differentiate immune states in type 1 diabetic families.
Chen YG; Cabrera SM; Jia S; Kaldunski ML; Kramer J; Cheong S; Geoffrey R; Roethle MF; Woodliff JE; Greenbaum CJ; Wang X; Hessner MJ
Diabetes; 2014 Nov; 63(11):3960-73. PubMed ID: 24760139
[TBL] [Abstract][Full Text] [Related]
20. Early Metabolic Endpoints Identify Persistent Treatment Efficacy in Recent-Onset Type 1 Diabetes Immunotherapy Trials.
Jacobsen LM; Cuthbertson D; Bundy BN; Atkinson MA; Moore W; Haller MJ; Russell WE; Gitelman SE; Herold KC; Redondo MJ; Sims EK; Wherrett DK; Moran A; Pugliese A; Gottlieb PA; Sosenko JM; Ismail HM;
Diabetes Care; 2024 Jun; 47(6):1048-1055. PubMed ID: 38621411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
